Improvements in lectin-glycan binding arrays and AI predictive models are necessary to expand the scope and reliability of glycan sequencing technology. In this study, we investigated how the deglycosylation of five lectins (DSL, PHA-E RCA-1, SNA, and WGA) may alter the binding signal between lectins and the model protein Fetuin B. We used Protein Deglycosylation Mix II to remove glycans from the lectins, validated deglycosylation by observing mobility shifts in SDS-PAGE gels, and conducted an ELISA to measure differences in lectin-protein binding between deglycosylated and non-deglycosylated lectin samples. We inputted the results from the ELISA into the Lewis Lab’s glycan sequencing AI model GlycoSeq and observed differences in the predicted glycoprofile between the deglycosylated and native lectin variants. However, further controlled experiments, including the purification of the lectins after deglycosylation, and updated model assumptions are required.
Optimizing glycan-lectin binding assays
Developing a comprehensive single-cell glycan profiling framework
Developing a link between the single-cell glycoprofile and pathological states
Improving diagnostic accuracy in differentiating healthy cells from diseased cells
Developing precision drug therapy to minimize off-target effects
While new developments in artificial intelligence have shown promising abilities to predict glycan profiling based on glycan-lectin binding, with lack of access to glycan-lectin binding information, it is unknown whether glycosylated lectins will have an impact on glycan sequencing predictions as compared to deglycosylated lectins.
Optimize lectin-glycan binding arrays
Validate the accuracy of the GlycoSeq AI model regardless of lectins being used for glycoprofiling
Increase access to glycan-binding data